INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2012

Curcumin dose may affect light-chain response and bone turnover in MGUS and SMM.

In a randomized, double-blind crossover study with 36 patients, participants received a 4g dose of curcumin or placebo for 3 months before crossing over, followed by an optional 8g open-label extension. Curcumin treatment decreased the free light-chain ratio and reduced the difference between clonal and nonclonal light chains. Urine DPYD, representing bone resorption, decreased with curcumin but rose with placebo, while serum creatinine tended to drop.

Study type
Randomized double-blind crossover trial and open-label extension
Who was studied
36 patients with MGUS or SMM
What was measured
Free light-chain response, bone turnover markers, and serum creatinine

THE PAPER

Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study.

Golombick T, Diamond TH, Manoharan A, Ramakrishna R. Am J Hematol, 2012.

PubMed 22473809 ↗DOI 10.1002/ajh.23159 ↗

CancerKidney healthBones & muscles

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.